A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany
Open Access
- 1 May 2019
- journal article
- research article
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 11, 319-331
Abstract
Background and objectives: Demand for assisted reproduction technology (ART) in Germany is high, with 100,844 treatment cycles during 2016. Many ART procedures involve ovarian stimulation with follicle stimulating hormone (FSH). Recently, biosimilar FSH products have become available. The objective of this study was to evaluate the cost-effectiveness of the recombinant FSH Gonal-f®, (Originator) in comparison to biosimilar follitropin alfa, Bemfola®, (Biosimilar 1) and Ovaleap®, (Biosimilar 2), from a German payer perspective in terms of cost per live birth. Methods: A decision tree model was developed, based on one cycle of assisted reproduction, to compare the original product to biosimilars. Clinical inputs, including live birth rates and adverse event rates were obtained from published randomized trials. Cost inputs were obtained from publicly available German sources. Clinical inputs, model structure and methodology were based on previous publications and validated by a clinical expert. Results: Results indicated that the live birth rate is higher for the Originator compared to Biosimilar 1 (40.7% vs 32.1% respectively), and Biosimilar 2 (32.2% vs 26.8%). The average cost per live birth for women treated with the Originator was estimated to be lower than those who were treated with biosimilars: Originator vs Biosimilar 1 (€10,510 vs €12,192), Originator vs Biosimilar 2 (€12,590 vs €13,606). The analysis also found that the Originator is associated with an incremental cost-effectiveness of €4,168 and €7,540 per additional live birth versus Biosimilar 1 and Biosimilar 2 respectively. Sensitivity analysis indicated probabilities of pregnancy, embryo transfer and live birth, were key drivers of model costs. Scenario analysis confirmed the robustness of the model outcomes. Conclusion: This study suggests that treatment with the Originator could result in a lower cost per live birth in comparison to biosimilars. Further analysis using real-world data, when available, is recommended to validate the results of the present study.Keywords
This publication has 25 references indexed in Scilit:
- Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement†‡Human Reproduction, 2014
- Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceHuman Reproduction Update, 2013
- The diversity of regulation and public financing of IVF in Europe and its impact on utilizationHuman Reproduction, 2012
- Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cyclesHuman Reproduction, 2011
- ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteriaHuman Reproduction, 2011
- Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cyclesCochrane Database of Systematic Reviews, 2011
- In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart reviewReproductive Biology and Endocrinology, 2010
- Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysisReproductive Biology and Endocrinology, 2010
- Who should pay for assisted reproductive techniques? Answers from patients, professionals and the general public in GermanyHuman Reproduction, 2010
- Follitropin-alfa for ovarian stimulation during assisted reproduction treatment: a national collaborative studyReproductive BioMedicine Online, 2001